晚期黑色素瘤完全缓解后选择性停用抗PD1免疫治疗的可持续应答
该研究评估125例晚期黑色素瘤患者(含脑转移)在完全缓解后选择性停用抗PD1为基础免疫治疗的结果。A组86例因完全缓解停药,B组39例因毒性或研究者决定停药后达完全缓解。中位随访38个月,仅7例复发,1例死于黑色素瘤,再挑战抗PD1仍有效。
要点
- 完全缓解后选择性停用抗PD1治疗可行,含脑转移患者。
- 因完全缓解停药与因毒性或研究者决定停药后达完全缓解者疗效相似。
- 复发后再挑战抗PD1治疗仍可获得再次缓解。
核心结论
- 完全缓解后停用抗PD1为基础免疫治疗在晚期黑色素瘤患者(含脑转移)中可行,两组疗效相似。
研究设计与样本
- 回顾性评估125例晚期黑色素瘤患者,接受抗PD1单药(N=97)或联合抗CTLA4(N=28)治疗。
- A组86例因完全缓解选择性停药,B组33例因治疗限制性毒性停药、6例因研究者决定停药后达完全缓解。
主要发现
- A组中位治疗持续时间22个月(范围5-49),中位达完全缓解时间9个月(范围2-47)。
- B组中位治疗持续时间3个月(范围0-36),中位达完全缓解时间7个月(范围1-32)。
- A组7例、B组3例出现疾病复发;停药后生存未达到。
- A组中位停药后应答时间19个月(范围0-42),B组25个月(范围0-66)。
- 脑转移患者中,A组中位停药后应答时间17个月(范围7-41),B组28个月(范围9-39)。
临床怎么用
- 晚期黑色素瘤患者达到完全缓解后可考虑选择性停用抗PD1为基础免疫治疗,包括脑转移患者。
- 停药后复发患者可再次挑战抗PD1治疗,仍可能获得缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-PD1-based immunotherapy is currently used in most patients with advanced melanoma. Despite the remarkable data regarding overall survival, the optimal treatment duration is still unknown. METHODS: We evaluated the outcome of 125 patients with advanced melanoma with and without brain metastases (MBM), treated either with anti-PD1 monotherapy (N = 97) or combined with anti-CTLA4 (N = 28) after elective treatment discontinuation due to complete response (CR) (group A, N = 86), or treatment-limiting toxicity (N = 33) and investigator's decision (ID, N = 6) (group B) with subsequent CR. RESULTS: For group A, median duration of treatment (mDoT) was 22 months (range 5-49) and median time to CR 9 months (range 2-47). Accordingly, mDoT for group B was 3 months (range 0-36) and median time to CR 7 months (range 1-32). Seven patients from group A and three from group B experienced disease recurrence. Off-treatment survival was not reached. Median off-treatment response time (mOTRt) was 19 months (range 0-42) and 25 months (range 0-66), respectively. For MBM, mOTRt was 17 months (range 7-41) and 28 months (range 9-39), respectively. After a median follow-up of 38 months (range 9-70), seven (5.6%) patients had deceased, one (0.8%) due to melanoma. CONCLUSIONS: Treatment discontinuation is feasible also in patients with MBM. Efficacy outcomes seemed to be similar in both groups of patients who achieved CR, regardless of reason for discontinuation. In patients who experienced disease relapse, treatment re-challenge with anti-PD1 resulted in subsequent renewed response.
引用
- Dimitriou F, Zaremba A, Allayous C, et al. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. Eur J Cancer. 2021. PMID: 33823361. doi:10.1016/j.ejca.2021.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。